The release of Natesto generics is anticipated after 17 March, 2034, following the expiration of its last patent.
Natesto is used to treat conditions associated with a deficiency or absence of endogenous testosterone. It provides a unique method of testosterone replacement therapy by nasally administering an effective amount of the testosterone gel formulation.
Natesto is protected by 5 patents, with the final one expiring on 17 March, 2034. Once these patents expire, generic versions of Natesto may be released. Below are the details of the patents: